In an era of market volatility and high inflation, companies in the life science industry are finding it harder to raise capital. For these companies, strategic planning and creative thinking are essential to secure consistent funding.

BPM’s Julie West, Michael VanderKlugt and Robert Houston explore the use of traditional reverse mergers as an option for life science startups. They argue that reverse mergers not only provide an efficient way to raise capital and enhance visibility but also offer an economical route to going public. They also underline the importance of due diligence, regulatory compliance and an understanding of the tax implications for any company considering this route.

Read the full article, “What Life Sciences Startups Can Do About Market Swings,” on Life Science Leader’s website. Please note that a subscription may be required to access the content.